BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2143 related articles for article (PubMed ID: 28076709)

  • 21. Evaluation of the Interaction of Amino Acid Infusion on
    Puszkiel A; Bauriaud-Mallet M; Bourgeois R; Dierickx L; Courbon F; Chatelut E
    Clin Pharmacokinet; 2019 Feb; 58(2):213-222. PubMed ID: 29736841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial).
    Ebbers SC; Braat AJAT; Moelker A; Stokkel MPM; Lam MGEH; Barentsz MW
    Trials; 2020 Feb; 21(1):141. PubMed ID: 32024533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
    Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A
    Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroendocrine Tumor Therapy:
    Mittra ES
    AJR Am J Roentgenol; 2018 Aug; 211(2):278-285. PubMed ID: 29949416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
    Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Blumberg J; Ruszniewski P;
    N Engl J Med; 2014 Jul; 371(3):224-33. PubMed ID: 25014687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.
    Delpassand ES; Samarghandi A; Zamanian S; Wolin EM; Hamiditabar M; Espenan GD; Erion JL; O'Dorisio TM; Kvols LK; Simon J; Wolfangel R; Camp A; Krenning EP; Mojtahedi A
    Pancreas; 2014 May; 43(4):518-25. PubMed ID: 24632546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Efficacy of 177 Lu-DOTATATE in Children and Young Adult Population : A Single-Center Experience.
    Aggarwal P; Satapathy S; Sood A; Singh H; Mittal BR; Lal S; Gupta R; Das CK; Yadav TD; Walia R
    Clin Nucl Med; 2024 Jul; 49(7):e312-e318. PubMed ID: 38769655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with
    Kunikowska J; Pawlak D; Bąk MI; Kos-Kudła B; Mikołajczak R; Królicki L
    Ann Nucl Med; 2017 Jun; 31(5):347-356. PubMed ID: 28316066
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Parghane RV; Talole S; Basu S
    Ann Nucl Med; 2021 Jan; 35(1):92-101. PubMed ID: 33135123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
    Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
    Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors.
    Vida Navas EM; Martínez Lorca A; Sancho Gutiérrez A; Sanz Gómez L; Navarro Martínez T; Grande Pulido E; Carrato Mena A; Gajate Borau P
    Front Endocrinol (Lausanne); 2021; 12():676973. PubMed ID: 33935979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors.
    Sansovini M; Severi S; Ambrosetti A; Monti M; Nanni O; Sarnelli A; Bodei L; Garaboldi L; Bartolomei M; Paganelli G
    Neuroendocrinology; 2013; 97(4):347-54. PubMed ID: 23392072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and outcomes of
    Lin E; Chen T; Little A; Holliday L; Roach P; Butler P; Hosking E; Bailey E; Elison B; Currow D
    Intern Med J; 2019 Oct; 49(10):1268-1277. PubMed ID: 31062490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
    Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
    J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with
    Strosberg JR; Srirajaskanthan R; El-Haddad G; Wolin EM; Chasen BR; Kulke MH; Bushnell DL; Caplin ME; Baum RP; Hendifar AE; Öberg K; Ruszniewski P; Santoro P; Broberg P; Leeuwenkamp OR; Krenning EP
    J Nucl Med; 2021 Mar; 62(12):1712-8. PubMed ID: 33771903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concomitant 177Lu-DOTATATE and Capecitabine Therapy in Patients With Advanced Neuroendocrine Tumors: A Long-term-Outcome, Toxicity, Survival, and Quality-of-Life Study.
    Ballal S; Yadav MP; Damle NA; Sahoo RK; Bal C
    Clin Nucl Med; 2017 Nov; 42(11):e457-e466. PubMed ID: 28872545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC.
    Severi S; Sansovini M; Ianniello A; Bodei L; Nicolini S; Ibrahim T; Di Iorio V; D'Errico V; Caroli P; Monti M; Paganelli G
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1955-63. PubMed ID: 26112388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lutetium-labelled peptides for therapy of neuroendocrine tumours.
    Kam BL; Teunissen JJ; Krenning EP; de Herder WW; Khan S; van Vliet EI; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1(Suppl 1):S103-12. PubMed ID: 22388631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.
    Nicolini S; Bodei L; Bongiovanni A; Sansovini M; Grassi I; Ibrahim T; Monti M; Caroli P; Sarnelli A; Diano D; Di Iorio V; Grana CM; Cittanti C; Pieri F; Severi S; Paganelli G
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3260-3267. PubMed ID: 33604690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based
    Sundlöv A; Gleisner KS; Tennvall J; Ljungberg M; Warfvinge CF; Holgersson K; Hallqvist A; Bernhardt P; Svensson J
    Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3830-3840. PubMed ID: 35451612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 108.